DG, ICMR and Director CSIR-NIScPR release special issues of Vigyan Pragati & Science Reporter magazines

Science communication brings behavioural changes

LyGenesis and Imagine Pharma to jointly develop cell therapies for Patients with Type 1 diabetes

Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes

Cipla signs agreement with Novartis for diabetes therapy Galvus range

Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore

Thermo Fisher Scientific expands its capabilities in France

Bourgoin early development hub broadens offerings for oral solid dose formulations

Approx 800 million Indians do not have health coverage, says Expert

Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand

Israeli researchers develop an effective drug to prevent muscle diseases

The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.

EIP Pharma and Diffusion Pharmaceuticals inks agreement to create CNS-focused company

EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging

Hutchmed completes rolling submission of NDA to USFDA for fruquintinib

NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China

Heartfulness signs hits a new milestone by signing an MoU with AIIMS

MPP signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of HIV prevention medicine

Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers